AN2 Therapeutics Nets $80 million for Novel Lung Disease Program
California-based AN2 Therapeutics secured $80 million in Series B funding round to help advance its novel nontuberculous mycobacterial lung disease program.
Source: biospace.com
Stay updated with breaking news from Eli Lillyexecutive. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
California-based AN2 Therapeutics secured $80 million in Series B funding round to help advance its novel nontuberculous mycobacterial lung disease program.